Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabuzalgron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 9/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 11/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabuzalgron SCHEMBL19285840 | 0.99 | ADRA1A (0.98) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Dabuzalgron SCHEMBL5200715 | 0.99 | ADRA1A (0.98) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5201030 | 0.89 | ADRA1A (0.80) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5200474 | 0.87 | ADRA1A (0.77) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5203525 | 0.86 | ADRA1A (0.75) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL22596705 | 0.84 | ADRA1A (0.73) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5204186 | 0.80 | ADRA1A (0.67) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5202260 | 0.80 | ADRA1A (0.66) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5201322 | 0.79 | ADRA1A (0.65) | ADRA1ANISCHHTR1AADRA2AADRA2B | |
| SCHEMBL5201551 | 0.78 | ADRA1A (0.64) | ADRA1ANISCHHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590107-B2 | Methods for treating neurological disorders with α1A-AR partial agonists | CURASEN THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| US-20220401415-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA1A-AR PARTIAL AGONISTS | CURASEN THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| EP-4048263-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA 1A-AR PARTIAL AGONISTS | Curasen Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | claimed |
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | claimed |
| JP-2007509897-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | claimed |
| US-20040170689-A1 | Stabilized formulations comprising hydrolytically unstable compositions | ODINK DEBRA ALIDA (US) | 2004-09-02 | — | — | US | claimed |
| EP-1341529-A2 | HYDROLYTICALLY UNSTABLE COMPOSITIONS | F. Hoffman-la Roche AG (CH) | 2003-09-10 | — | — | EP | claimed |
| US-20020086057-A1 | Stabilized fromulations comprising hydrolytically unstable compositions | SYNTEX (U.S.A.) LLC | 2002-07-04 | — | — | US | claimed |
| WO-2002038133-A2 | COMPOSITIONS CONTAINING HYDROLYTICALLY UNSTABLE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | claimed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | claimed |
| US-20260014159-A1 | DEVELOPMENT OF ALPHA-1A-ADRENERGIC RECEPTOR AGONISTS AS A THERAPY TO TREAT HEART FAILURE | US GOV VETERANS AFFAIRS (US) | 2026-01-15 | — | — | US | disclosed |
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250188060-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20020086057-A1 | Stabilized fromulations comprising hydrolytically unstable compositions | SYNTEX (U.S.A.) LLC | 2002-07-04 | — | — | US | disclosed |
| WO-2002038133-A2 | COMPOSITIONS CONTAINING HYDROLYTICALLY UNSTABLE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRA1A 6/4885NISCH 1361/4885HTR1A 207/4885 |
| US-20020086057-A1 | Stabilized fromulations comprising hydrolytically unstable compositions | SI, LIPA, HDAC2 | ADRA1A 2304/4885NISCH 1994/4885HTR1A 1230/4885 |
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | ADRA1A, ADRB1, ADRA1D | ADRA1A 1/4885NISCH 4043/4885HTR1A 13/4885 |
| US-20220401415-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH ALPHA1A-AR PARTIAL AGONISTS | ADRA2A, ADRA1A, HTR1A | ADRA1A 2/4885NISCH 1973/4885HTR1A 3/4885 |
| US-11590107-B2 | Methods for treating neurological disorders with α1A-AR partial agonists | ADRA2A, ADRA1A, HTR1A | ADRA1A 2/4885NISCH 2025/4885HTR1A 3/4885 |
| US-20250188060-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRB1, ADRA1A, ADRA1D | ADRA1A 2/4885NISCH 1791/4885HTR1A 41/4885 |
| US-20260014159-A1 | DEVELOPMENT OF ALPHA-1A-ADRENERGIC RECEPTOR AGONISTS AS A THERAPY TO TREAT HEART FAILURE | ADRB1, ADRA1D, ADRB3 | ADRA1A 4/4885NISCH 3782/4885HTR1A 32/4885 |
| US-20040170689-A1 | Stabilized formulations comprising hydrolytically unstable compositions | SI, LIPA, CEL | ADRA1A 2077/4885NISCH 1791/4885HTR1A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.